Fresh Tracks Therapeutics, Inc. (FRTX)
(Delayed Data from OTC)
$0.88 USD
0.00 (0.00%)
Updated Aug 8, 2024 03:02 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
FRTX 0.88 0.00(0.00%)
Will FRTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FRTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FRTX
Fresh Tracks Therapeutics (FRTX) Reports Q3 Loss, Tops Revenue Estimates
FRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for FRTX
Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
Clover Health Investments And 2 Other Stocks Under $1 Insiders Are Buying